# US 2016/0250164 A1 · Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alfa-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250164 A1
- Document ID: US20160250164A1
- Status: Published application
- Kind: A1
- Application number: 14/984,744
- Filed: 2015-12-30
- Published: 2016-09-01
- Earliest claimed: 2007-10-02
- Assignees: Rigshospitalet
- Applicants: Rigshospitalet
- Inventors: Pär Johansson; Niels H. Secher; Louise Bochsen
- Web page: https://patentgrep.com/patent/US20160250164A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- G01N 33/9433: {(Nor)adrenaline}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a novel use and methods of treatment using sympathicomimetic agonists with pro-hemostatic activity.

## Claims

### Claim at position 1

-89. (canceled)

### Claim 90

A method for treatment or prophylaxis of bleeding in a subject with subnormal clot strength and stability, the method comprising administration of an effective amount of an adrenergic receptor agonist to said subject.

### Claim 91 (depends on 90)

The method according to claim 90, wherein the adrenergic receptor agonist is adrenaline or noradrenaline.

### Claim 92 (depends on 90)

The method according to claim 90, wherein the adrenergic receptor agonist is administered in the range 0.1 to 100 microgram/kg.

### Claim 93 (depends on 90)

The method according to claim 90, wherein the adrenergic receptor agonist is administered in the range 0.1 microgram/kg/hour to 25 microgram/kg/hour.

### Claim 94 (depends on 90)

The method according to claim 90, wherein the adrenergic receptor agonist is administered in the range 0.1 microgram/kg/hour to 20 microgram/kg/hour.

### Claim 95 (depends on 90)

The method according to claim 90, wherein the adrenergic receptor agonist is administered in the range 1 microgram/kg/hour to 10 microgram/kg/hour.

### Claim 96 (depends on 90)

The method according to claim 90, wherein the adrenergic receptor agonist is administered systemically.

### Claim 97 (depends on 90)

The method according to claim 90, wherein the adrenergic receptor agonist is administered intravenously.

### Claim 98 (depends on 90)

The method according to claim 90, wherein the adrenergic receptor agonist is administered by intravenous infusion.

### Claim 99 (depends on 90)

The method according to claim 90, wherein the adrenergic receptor agonist is administered continuously.

### Claim 100 (depends on 90)

The method according to claim 90, wherein the administration results in a systemic concentration of the adrenergic receptor agonist.

### Claim 101 (depends on 90)

The method according to claim 90, wherein the subject is human.

### Claim 102 (depends on 90)

The method according to claim 90, wherein the subject is suffering from thrombocytopenia.

### Claim 103 (depends on 102)

The method according to claim 102, wherein the thrombocytopenia is caused by decreased bone marrow production of megakaryocytes.

### Claim 104 (depends on 90)

The method according to claim 90, wherein the bleeding in said subject is caused by a combination of coagulopathy and thrombocytopenia.

### Claim 105 (depends on 90)

The method according to claim 90, wherein the subnormal clot strength and stability in said subject is due to low platelet function.

### Claim 106 (depends on 90)

The method according to claim 90, wherein the subject is suffering from drug-induced thrombocytopenia.

### Claim 107 (depends on 90)

The method according to claim 90, wherein the subject is suffering from chemotherapy-induced thrombocytopenia.

### Claim 108 (depends on 90)

The method according to claim 90, wherein administration of the adrenergic receptor agonist increases clot strength and stability in said subject.

### Claim 109

A method for treatment or prophylaxis of bleeding in a subject suffering from thrombocytopenia, the method comprising administration of an effective amount of an adrenergic receptor agonist to said subject.
